Anti-Von Willebrand Factor antibody [F8/86] (ab778)

Overview

• Product nameAnti-Von Willebrand Factor antibody [F8/86]
  See all Von Willebrand Factor primary antibodies
• Description
  Mouse monoclonal [F8/86] to Von Willebrand Factor
• Tested applicationsSuitable for: IHC-P, IHC-Frmore details
• Species reactivity
  Reacts with: Human
  Predicted to work with: Rabbit
• Immunogen

  Von Willebrand Factor isolated from human plasma.

Properties

• FormLiquid
• Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Store at -20°C or -80°C. Avoid freeze / thaw cycle.
• Storage bufferPreservative: 0.05% Sodium Azide
  Constituents: 1% BSA, Tissue culture supernatant
• PurityTissue culture supernatant
• ClonalityMonoclonal
• Clone numberF8/86
• IsotypeIgG1
• Light chain typekappa
• Research areas
  • Cardiovascular
  • Blood
  • Serum Proteins

  • Cardiovascular
  • Blood
  • Platelets

  • Cardiovascular
  • Blood
  • Coagulation
  • Extrinsic

  • Cardiovascular
  • Blood
  • Coagulation
  • Regulatory

  • Cancer
  • Invasion/microenvironment
  • Angiogenesis
  • Angiogenic growth factors

  • Stem Cells
  • Endothelial Progenitors
  • Endothelial Markers

  • Cardiovascular
  • Angiogenesis
  • Endothelial Cell Markers

Applications

Target

• FunctionImportant in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma.
• Tissue specificityPlasma.
• Involvement in diseaseDefects in VWF are the cause of von Willebrand disease (VWD) [MIM:277480]. VWD defines a group of hemorrhagic disorders in which the von Willebrand factor is either quantitatively or qualitatively abnormal resulting in altered platelet function. Symptoms vary depending on severity and disease type but may include prolonged bleeding time, deficiency of factor VIII and impaired platelet adhesion. Type I von Willebrand disease is the most common form and is characterized by partial quantitative plasmatic deficiency of an otherwise structurally and functionally normal Willebrand factor; type II is associated with a qualitative deficiency and functional anomalies of the Willebrand factor; type III is the most severe form and is characterized by total or near-total absence of Willebrand factor in the plasma and cellular compartments, also leading to a profound deficiency of plasmatic factor VIII.
• Sequence similaritiesContains 1 CTCK (C-terminal cystine knot-like) domain.
  Contains 4 TIL (trypsin inhibitory-like) domains.
  Contains 3 VWFA domains.
  Contains 3 VWFC domains.
  Contains 4 VWFD domains.
• DomainThe von Willebrand antigen 2 is required for multimerization of vWF and for its targeting to storage granules.
• Post-translational
  modificationsAll cysteine residues are involved in intrachain or interchain disulfide bonds.
  N- and O-glycosylated.
• Cellular localizationSecreted. Secreted > extracellular space > extracellular matrix. Localized to storage granules.

• Target information above from: UniProt accession P04275 The UniProt Consortium
  The Universal Protein Resource (UniProt) in 2010
  Nucleic Acids Res. 38:D142-D148 (2010) .

  Information by UniProt
• Database links
  • Entrez Gene: 7450 Human
  • Omim: 613160 Human
  • SwissProt: P04275 Human
  • Unigene: 440848 Human
• Alternative names
  • Coagulation factor VIII antibody
  • Coagulation factor VIII VWF antibody
  • F8VWF antibody

  • Factor VIII related antigen antibody
  • von Willebrand antigen 2 antibody
  • von Willebrand antigen II antibody
  • Von Willebrand disease antibody
  • VWD antibody
  • vWF antibody
  • VWF_HUMAN antibody

  see all